MajesTEC-9: A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
Study of Teclistamab In Patients with Multiple Myeloma
Sponsor: Janssen Research & Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAU7136
U.S. Govt. ID: NCT05572515
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to see how teclistamab by itself compares to study treatment combinations that are commonly used to treat multiple myeloma. These study treatment combinations are either pomalidomide, bortezomib and dexamethasone (called PVd) or carfilzomib and dexamethasone (called Kd). The patients will be randomly assigned to on of the study groups. The term "randomized" means something is done by chance or without any particular pattern, like flipping a coin to decide an outcome. The term study drug(s) refers to teclistamab and to the combinations PVd and Kd. Teclistamab, Carfilzomib-dexamethasone (Kd) combination have been approved by the U.S Food and Drug Administration (FDA). However, in this study teclistamab is considered experimental (not FDA approved) because it is being used for adults who have a type of cancer called multiple myeloma that came back or didn't respond to other treatments.
Divaya Bhutani, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with multiple myeloma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator